Company / R&D per Share
Wave Life Sciences Ltd. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.19
FY2025
5-year range
$1.19 / $2.68
FY2021-FY2025
Trend
-10.9%
vs FY2024
Sector context
#142 of 208
Health Care
What the data says
At $1.19, Wave Life Sciences Ltd.'s r&d per share ranks #142 of 208 in the Health Care sector. R&D per Share has declined for 5 consecutive years, from $5.11 in FY2020 to $1.19 in FY2025.
Based on SEC 10-K filings.
1.19 in FY2025 with a 5-year CAGR of -25.2%.
Declined from $1.50 to $1.19 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -16.3%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Sector benchmark
#142 of 208 in Health CareTop 68% of 208This company $1.19 Sector average $28.82
▼
-95.9% below sector average
Key checks
Key Insights
- Wave Life Sciences Ltd.'s r&d per share has declined for 5 consecutive years.
- In FY2025, r&d per share decreased 10.9% year-over-year.
- Ranks #142 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.19 | -10.9% |
| FY2024 | $1.34 | -10.4% |
| FY2023 | $1.50 | -26.6% |
| FY2022 | $2.04 | -24.1% |
| FY2021 | $2.68 | -47.5% |
| FY2020 | $5.11 | +89.8% |
| FY2019 | $2.69 | -44.3% |
| FY2018 | $4.83 | +43.1% |
| FY2017 | $3.37 | +78.2% |
| FY2016 | $1.89 | +320.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026